| Bid | 7.5 |
| Market Cap | 372.12M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.68 |
| PE Ratio (ttm) | -2.05 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7.53 |
| Volume | 61,307 |
| Avg. Volume (20D) | 358,993 |
| Open | 7.69 |
| Previous Close | 7.40 |
| Day's Range | 7.50 - 7.85 |
| 52-Week Range | 7.30 - 16.88 |
| Beta | undefined |
About KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed ...
Analyst Forecast
According to 6 analyst ratings, the average rating for KALV stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 271.85% from the latest price.
2 months ago · businesswire.com
KalVista Pharmaceuticals to Present at Upcoming Investor ConferencesCAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following inv...
